Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease

D. A. Stetler, K. M. Rose, M. E. Wenger, C. M. Berlin, S. T. Jacob

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.

Original languageEnglish (US)
Pages (from-to)7499-7503
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume79
Issue number23 I
DOIs
StatePublished - Dec 1 1982

Fingerprint

RNA Polymerase I
Rheumatic Diseases
Autoimmune Diseases
Peptides
Antibodies
Serum
Mixed Connective Tissue Disease
Systemic Lupus Erythematosus
Radioimmunoassay
Immunoglobulins
Rheumatoid Arthritis
Hydralazine
Antibody Formation
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • General

Cite this

@article{98792121cb8c4d32b3b673830cf2e7e2,
title = "Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease",
abstract = "Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78{\%} of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.",
author = "Stetler, {D. A.} and Rose, {K. M.} and Wenger, {M. E.} and Berlin, {C. M.} and Jacob, {S. T.}",
year = "1982",
month = "12",
day = "1",
doi = "10.1073/pnas.79.23.7499",
language = "English (US)",
volume = "79",
pages = "7499--7503",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "23 I",

}

Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease. / Stetler, D. A.; Rose, K. M.; Wenger, M. E.; Berlin, C. M.; Jacob, S. T.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 79, No. 23 I, 01.12.1982, p. 7499-7503.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease

AU - Stetler, D. A.

AU - Rose, K. M.

AU - Wenger, M. E.

AU - Berlin, C. M.

AU - Jacob, S. T.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.

AB - Sera from patients with rheumatic autoimmune diseases were screened for antibodies directed against RNA polymerase I by using a solid-phase radioimmunoassay. Significant levels of the antibodies were detected in the sera of all patients with either systemic lupus erythematosus or mixed connective tissue disease and in 78% of the individuals with rheumatoid arthritis. No detectable anti-RNA polymerase I antibodies were found in the sera from healthy subjects. Individuals taking hydralazine, three of whom exhibited symptoms of drug-induced lupus, had barely detectable levels of the antibodies. Immunoglobulins obtained from sera containing anti-RNA polymerase I antibodies, as determined by the radioimmunoassay, could inhibit RNA polymerase I activity in vitro. Sera from patients with systemic lupus erythematosus contained immunoglobulins directed against the polymerase I-associated polypeptide of M[r] 65,000 as well as against the polypeptides of M[r] 120,000 or M[r] 25,000, or both. Sera from individuals with rheumatoid arthritis reacted with the polypeptide of M[r] 65,000 only. The antibodies in the sera of patients with mixed connective tissue disease were directed against the M[r] 42,000 polypeptide or a combination of the M[r] 65,000, 42,000, and 25,000 polypeptides. These data suggest that the production of anti-RNA polymerase I antibodies may be a unique characteristic of individuals with rheumatic autoimmune diseases and that the production of antibodies against specific polypeptides of RNA polymerase I may be indicative of the particular class of disease.

UR - http://www.scopus.com/inward/record.url?scp=0020452231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020452231&partnerID=8YFLogxK

U2 - 10.1073/pnas.79.23.7499

DO - 10.1073/pnas.79.23.7499

M3 - Article

C2 - 6961426

AN - SCOPUS:0020452231

VL - 79

SP - 7499

EP - 7503

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 23 I

ER -